COCP selects oral protease inhibitors—still in preclinical stage—for SARS-CoV-2: https://www.globenewswire.com/news-release/2022/01/27/2374281/0/en/Cocrystal-Pharma-Selects-Two-Lead-Antiviral-Drug-Candidates-for-its-COVID-19-Oral-Drug-Program.html COCP’s previously disclosed protease inhibitor for SARS-CoV-2, CDI-45205, is not oral.